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Abstract
Aim—This study was designed to determine any rebleeding after atorvastatin treatment following 
spontaneous intracerebral hemorrhage (ICH) in a prospective safety trial.
Patients—Atorvastatin (80 mg/day) therapy was initiated in 6 patients with primary ICH with 
admission Glasgow Coma Score (GCS) >5 within 24 hours of ictus and continued for 7 days, with 
the dose tapered and treatment terminated over the next 5 days. Patients were studied 
longitudinally by multiparametric magnetic resonance imaging (MRI) at three time points: acute 
(3 to 5 days), subacute (4 to 6 weeks) and chronic (3 to 4 months). Imaging sequences included 
T1, T2-weighted imaging (T2WI), diffusion tensor imaging (DTI) and contrast-enhanced MRI 
measures of cerebral perfusion, blood volume and blood-brain barrier (BBB) permeability. 
Susceptibility weighted imaging (SWI) was used to identify primary ICH and to check for 
secondary rebleeding. Final outcome was assessed using Glasgow Outcome Score (GOS) at 3-4 
months.
Results—Mean admission GCS was 13.2±4.0 and mean GOS at 3 months was 4.5±0.6. 
Hemorrhagic lesions were segmented into core and rim areas. Mean lesion volumes decreased 
significantly between the acute and chronic study time points (p=0.008). Average ipsilateral 
hemispheric tissue loss at 3 to 4 months was 11.4±4.6 cm3. MRI showed acutely reduced CBF 
(p=0.004) and CBV (p=0.002) in the rim, followed by steady normalization. Apparent diffusion 
coefficient of water (ADC) in the rim demonstrated no alterations at any of the time points 
(p>0.2). The T2 values were significantly elevated in the rim acutely (p=0.02), but later returned to 
baseline. The ICH core showed sustained low CBF and CBV values concurrent with a small 
reduction in ADC acutely, but significant ADC elevation at the end suggestive of irreversible 
injury.
Conclusion—Despite the presence of a small, probably permanent, cerebral lesion in the ICH 
core, no patients exhibited post-treatment rebleeding. These data suggest that larger, Phase 2 trials 
are warranted to establish long term clinical safety of atorvastatin in spontaneous ICH.
*Corresponding author: Knight RA, Department of Neurology-NMR Research, Henry Ford Hospital, 2799 West Grand Blvd., Detroit, 
MI 48202, USA.
#These authors contributed equally to the manuscript.
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Introduction
Intracerebral hemorrhage (ICH) is a particularly lethal stroke subtype, with first year 
mortality approaching 50% and survivors often left with severe disabilities [1]. This poor 
outcome results from direct tissue damage and mass effect caused by the hematoma, and the 
presence of an ischemic or partially ischemic perihematomal boundary. In addition, the 
hematoma itself has been reported to induce other early secondary tissue changes including 
neuronal and glial loss due to apoptosis and inflammation [2], and vasogenic edema caused 
by damage to the blood-brain barrier (BBB) [1,3]. While spontaneous ICH accounts for 
10-20% of all strokes, effective clinical treatments remain elusive.
Statin (3-hydroxy-3-methyl-glutaryl-coenzyme A [HMG-CoA] reductase inhibitor) therapy 
has been reported to modulate endothelial function and preserve blood flow in ischemic 
tissue [4] and to exert neuroprotection due to pleiotropic effects via upregulation of 
angiogenesis, neurogenesis and synaptogenesis [5-7]. Statins have also shown therapeutic 
benefit following experimental ICH [8-16] and in clinical ICH setting [17-23]. However, 
despite several studies reporting neuroprotective effects of statins in cerebrovascular 
diseases, reservations persist regarding their clinical use in ICH, with a presumed increased 
risk of hemorrhage recurrence with statin treatment [24-26].
These circumstances have resulted in uncertainty regarding statin therapy in acute ICH 
[27-28]. However, with virtually no other effective therapies available for this extremely 
debilitating and high mortality condition, trials in humans are urgently needed to 
comprehensively test the efficacy of statins [29]. This prospective, nonrandomized trial 
evaluated the safety of statin treatment with respect to hemorrhage recurrence after primary 
ICH event in a patient cohort with an admission GCS >5. In addition to clinical evaluations, 
patients also underwent serial MRI investigations to assess ICH-induced changes in cerebral 
blood flow and volume, BBB permeability, edema and hemorrhage recurrence at acute, sub-
acute and chronic time points.
Materials and Methods
Patient selection and treatment
Atorvastatin (80 mg/day) therapy was initiated in ICH patients (mean age 52.7 ± 12.4 years) 
with GCS greater than 5 within 24 hours of ictus. Treatment was continued for 7 days, and 
then tapered off over 5 days (20 mg/day × 3 days followed by 10 mg/day × 2 days). Final 
neurological outcome was assessed via the GOS at 3 to 4 months. Exclusion criteria 
included prior statin use, preexisting severe neurological conditions, ICH less than 2 cm 
maximum diameter, cranial arteriovenous malformations, aneurysm, tumor, trauma, 
pregnant, elevated CPK or myocardial infarction within 30 days. This study was approved 
by the Institutional Review Board committee (IRB# 3921).
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MRI protocol
Patients were studied longitudinally by MRI at three time points (acute = 3 to 5 days, 
subacute = 4 to 6 weeks, and chronic = 3 to 4 months). Two of the 6 patients were not 
studied at the subacute time point. All MRI studies were performed using a 3 Tesla 94 cm 
bore, Food and Drug Administration (FDA) approved clinical MRI system (GE Medical 
Systems, Milwaukee, WI) running Excite HD (software version 12.0) with a gradient 
subsystem capable of producing field gradients of 40 mT/m and 150 T/m/sec slew rate. An 
8-channel phased array head coil was used for signal reception. The imaging protocol 
included multislice T1, T2, flow-compensated susceptibility-weighted imaging (SWI), 
diffusion-tensor imaging (DTI), and a spiral Look-Locker (L-L) imaging sequence for T1 
mapping. Contrast enhancement was used in conjunction with MRI pulse sequences 
designed to measure changes in cerebral perfusion, blood volume and blood-brain barrier 
permeability. Dynamic contrast enhancement was produced by injecting 20 ml of Magnevist 
(gadopentetate dimeglumine; Bayer Healthcare Pharmaceuticals, Wayne, NJ) as an 
intravenous bolus at a rate of 4 ml/second using an Opti-Star power injector (Mallinckrodt, 
Hazelwood, MO). The number of slices was adjusted to encompass the entire region of the 
hematoma and surrounding rim. Imaging parameters for the various sequences are described 
in the following sections.
Standard MR imaging sequences
At each study time, a set of standard imaging sequences was obtained to evaluate the 
location, size and paramagnetic characteristics of the hematoma core and rim area over time 
before collecting the quantitative dynamic contrast enhanced MRI data. First, an SWI 
sequence was acquired using a 3-dimensional (3D) spoiled gradient recalled acquisition in 
the steady state (SPGR) sequence with repetition time (TR) = 33 ms, echo time (TE) = 20 
ms, flip angle (FA) = 15 degree, bandwidth (BW) = 15.63 kHz, FOV = 24 cm, imaging 
matrix 512 × 512, 2 mm slice thickness, and 1 average with flow compensation.
Next, a 3D inversion recovery SPGR (3D-IRSPGR) volumetric scan was acquired with 
TE/TI/TR of 3.5/500/8.8 msec, flip angle 15°, imaging matrix 256 × 192 × 172, 24 cm field 
of view (FOV), phase FOV 0.75, 1 mm slice thickness. A transverse relaxation (T2) 
weighted imaging sequence was used to acquire T2-weighted images (T2WI), which were 
subsequently used to identify and localize the hematoma region and surrounding edematous 
rim. The images were acquired using a fast multi echo sequence with TR/TE = 2500/30 and 
117 ms, imaging matrix = 320 × 224, FOV = 24 cm, and 4 mm slice thickness.
Finally, diffusion tensor imaging (DTI) [30,31] was acquired to determine whether 
diffusion-weighted imaging could be used to detect post-ICH tissue recovery, particularly of 
white matter, in adjacent regions bordering the hematoma (the rim). The sequence used an 
echo-planar imaging (EPI) sequence with TR/TE = 6500/92 ms, field of view = 24 cm, 96 × 
96 imaging matrix, slice thickness = 2.6 mm, b-value = 1500 s/mm2, 55 directions, 1 
average.
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Contrast enhanced MRI sequences
In this study, dynamic contrast-enhanced MRI (DCE-MRI) was used to generate quantitative 
estimates of cerebral blood flow (CBF), cerebral blood volume (CBV) and pre and post-
contrast T1 images to check for contrast enhancement by subtraction. Initial baseline T1-
weighted images (T1WI) were obtained using a fast spin-echo (FSE) sequence with TE = 14 
ms, TR = 2500 ms, 24 cm FOV, imaging matrix 320 × 224, and 4 mm slice thickness. To 
obtain a baseline level for localizing BBB permeability, a fast Look-Locker T1-weighted 
spiral EPI sequence (TR/TE = 1800/5.7 ms, xres of 4096, yres of 4, 24 cm FOV, three 4 mm 
thick slices) was used to obtain quantitative estimates of T1 prior to and following contrast 
injection.
Before acquiring the BBB permeability data, DCE-MRI based estimates of CBF and CBV 
were obtained [32-34]. For measurements of CBF and CBV, a spin-echo EPI sequence was 
used with 128 × 128 data acquisition matrix, TR/TE = 1900/24.2 ms, 24 cm FOV, to image 
nine 4 mm thick slices. The DCE cerebral perfusion measurement acquired 99 sets of EPI 
images; ten sets before Magnevist injection and 89 sets after. After acquiring the CBF/CBV 
data set, a series of quantitative post-contrast T1 measurements were collected to track 
estimates the clearance of the contrast agent over time. Six sets of T1 estimates were 
acquired using the fast Look-Locker T1-weighted spiral EPI sequence described above.
Finally, after collecting the BBB permeability data set, a final post-contrast T1WI data set 
was obtained using the previously described T1WI FSE sequence. Identification of core and 
border (rim) regions of interest was performed by thresholding T2 values and estimates of 
lesion volume (core + rim) and hemispheric tissue loss were measured from T2WI. 
Measures of T2 and the apparent diffusion coefficient (ADC) were obtained from the T2WI 
and DTI data sets, respectively. Estimates of CBF and CBV were calculated for each time 
point using the DCE-MRI data sets with Eigen tool analysis [35]. Brain regions with 
changes in vascular permeability were identified by subtracting pre-contrast T1 from post-
contrast T1 images.
All data are reported as mean ± standard deviation (sd) and were analyzed using Student’s t-
tests. Significance was inferred for p<=0.05.
Results
Six patients (3 male and 3 female) with ICH were studied (mean age 52.7 ± 12.4 years). All 
ICH loci were deep and 3 were left-sided. The mean GCS at admission was 13.2±4.0 and the 
mean GOS at 3 months was 4.5+0.6. No patients re hemorrhaged during the study and none 
were dropped due to drug-related complications. Mean lesion volume decreased 
significantly between the acute and chronic time points (Figure 1). Average ipsilateral 
hemispheric tissue loss at 3 to 4 months ranged from about 6 cc to 17 cc with a mean of 
11.4±4.6 cc.
The T2WI and SWI sequences provided excellent discrimination of the ICH core and rim 
areas at all time points studied. A temporal series of T2WI, SWI, T1 subtraction and CBV 
images from a representative ICH patient obtained at acute, sub-acute and chronic time 
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points are shown in Figure 2. Dramatic shifts in T2 signal intensity were seen in the core and 
rim areas between acute and sub-acute time points. Average T2±SD values are shown plotted 
as a function of time in Figure 3. The T2 values were significantly elevated in the rim area 
acutely (p=0.02), but returned to baseline at the subacute and chronic time points. In the 
core, T2 values decreased acutely, increased sub-acutely, and then declined again at the 
chronic time with the changes differing significantly from contralateral levels at all three 
times.
Temporal changes in CBF for the core and rim areas are shown in Figure 4. Estimates of 
CBV obtained from the same MRI data sets closely tracked with CBF changes and are not 
shown. MRI revealed significant reductions in CBF (p=0.004) and CBV (p=0.002), relative 
to contralateral ROI values, in the ICH rim area acutely that improved with time. The initial 
low CBF and CBV levels measured in the rim were followed by steady normalization at the 
subacute and chronic time points with significant improvement in CBV (p=0.035) and 
marginally significant improvement (p=0.055) in CBF observed between acute and chronic 
time points. Similar findings of acute time point reductions in CBF (p=0.001) and CBV 
(p=0.002) were also seen in the core area. In contrast, CBF and CBV levels in the ICH core 
region appeared to worsen slightly at the sub-acute time point and then improve at the 
chronic time point. The degree of recovery in the core between acute and chronic time 
points, however, was not significant.
Lastly, estimates of ADC are shown in Figure 5. The rim area demonstrated no significant 
changes at any of the time points (p>0.2) relative to contralateral values or across time; 
however, in the hematoma core region ADC values declined significantly (p=0.01) at the 
acute time before rebounding back to or slightly above contralateral levels at the subacute 
and chronic time points. A significant increase in core ADC values (p=0.05) was also noted 
between the acute and chronic studies. It should be noted that although DTI methods were 
used to measure ADC, we were not able to generate estimates of fractional anisotropy in the 
ICH region due to poor signal to noise.
Discussion
Using serial multiparametric MRI methods, this small, prospective safety trial of atorvastatin 
treatment following acute ICH demonstrated no hemorrhage recurrence in subjects with a 
GCS of >5. All subjects showed ICH resolution and lesion size decreased with time. It 
should be noted, however, that the loci of ICH in all subjects were deep with no lobar 
participation. While acute CBF and CBV levels suggest lower blood flow in the ICH rim, 
the ADC did not demonstrate corresponding changes that would be associated ischemia. 
Conversely, MRI measures from the core area showed sustained low CBF values concurrent 
with a small reduction in ADC levels acutely and significant elevation of ADC at the chronic 
time point suggesting irreversible injury in this region.
The observations herein support previous reports on statin use before and/or after ICH [36] 
and decision analysis-based recommendations on possible statin use in acute non-lobar ICH 
[25]. Furthermore, imaging may be of assistance in the clinical approach to statin use for 
ICH. In the pharmacological treatment of clinical ICH, there is an opportunity to improve 
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patient recovery, as most will not benefit significantly from current application of surgical 
clot removal, although additional minimally invasive, novel catheter based clot removal 
strategies such as Surgical Trial in Traumatic intra Cerebral Haemorrhage (STICH) have 
been investigated [37]. In addition, medical-based therapy with clot stabilization has not 
become a standard treatment [20,21,37,38]. The recently published STICH-II trial results, 
however, argue for surgical intervention in superficial lobar ICH without ventricular 
hemorrhage [39]. Thus, even while excluding drug therapy for purely lobar hemorrhages, a 
pharmacological approach may be of some benefit in non-lobar ICH.
Statin use in the context of a recent stroke, either ischemic or hemorrhagic, has undergone a 
surge of recent interest as the multifaceted beneficial effects of these compounds have been 
observed in the laboratory as well as in clinical studies. In the large Stroke Prevention by 
Aggressive Reduction in Cholesterol Levels (SPARCL) trial, high-dose atorvastatin (80 mg) 
administered after a transient ischemic attack or ischemic stroke was found to be clinically 
beneficial with an absolute 5-year stroke risk reduction of 2.2% [5,40]. In two independent 
clinical studies, prior statin use in patients who experienced an ICH was associated with 
reduced mortality and a higher chance of a good outcome [18,20,21]. Experimentally, statins 
have been shown to be neuroprotective and endothelial protective acutely after stroke [41]. 
Statins also improve brain recovery subacutely due to their influence on endogenous 
progenitor cells and by enhancing neurogenesis and angiogenesis [12,15].
In ICH patients that have undergone craniotomy with biopsy of the perihematomal regions, 
there is evidence of neurogenesis in the adult brain [42]. A medical therapy, such as a statin, 
which might increase this endogenous brain neurogenesis has therapeutic appeal because of 
the broad window of administration during the days and weeks after ICH. In laboratory 
studies using a rodent intracerebral blood injection model of ICH, statins improved 
neurological function by 2 weeks post ICH, and induced angiogenesis, neurogenesis, and 
synaptogenesis by 4 weeks after ICH [12,13]. Using the collagenase model of ICH in rats, 
atorvastatin-treated animals demonstrated significantly improved neurological functional 
scores and less hemispheric atrophy, as well as less brain edema at 3 days post ICH [11]. In 
more recent animal studies, we have used MRI to measure physiological and structural 
changes in the brain across time in statin-treated animals; there was good correlation 
between tissue loss measurements by MRI and histological methods, and both methods 
showed less tissue loss with atorvastatin treatment [12]. In addition, there was significant 
reduction of BBB permeability and edema, with increased CBF in the post ICH statin-
treated animals [15]. These findings suggest the need for further statin treatment studies in 
clinical ICH patients.
Relationship between decreasing total and low density lipoprotein (LDL) levels and elevated 
risk of ICH has been suggested by some studies. For instance, Phuah and co-workers 
reported a steep decrease in total cholesterol and LDL levels 6 months prior to the onset of 
ICH in a patient population of 212 [43]. Most patients in this study were reported to have 
serum levels of total cholesterol between 170-180 mg/dl, a mean decrease from about 190 
mg/dl 24 months pre-ICH. The authors suggested a causative link between accelerated 
decline in cholesterol and the risk of ICH. The total cholesterol levels in the population we 
studied ranged between 105-208 mg/ dl at ICH onset and exceeded the narrow range 
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reported by these authors. More work is clearly needed to firmly establish any links between 
increased risk of ICH and rapid decline in total cholesterol and LDL levels. Possible 
mechanisms are suggested to be weakening of endothelial and microvascular walls due to 
increased broad inflammatory processes that are reflected in quick lipid reduction or direct 
structural weakening of vascular walls due to changes in membrane phospholipid 
composition [44]. In addition, Eisa-Beygi and Rezaei suggest that mutations in the genes or 
pharmacological perturbations of their gene-products and signaling mechanisms that 
regulate developmental neurovascular stabilization are likely to underlie the etiology of 
some forms of spontaneous ICH in humans [45]. However, despite this complex scenario, 
the clinical benefits of statin uses are believed to outweigh a slightly increased probability of 
post-stoke bleeding in the population at risk [46].
In the current study, atorvastatin was administered for 12 days after ICH; clinical features 
were noted and both early and delayed MRI studies were obtained. This represents the first 
prospective trial of a statin after ICH with correlative MRI analysis. These findings highlight 
the feasibility of combining a clinical therapeutic with advanced imaging to follow patient 
recovery. Yoshioka and colleagues employed MRI to follow outcome after ICH without 
experimental treatment, and have shown that fractional anisotropy using diffusion tensor 
tractography could predict motor functional outcome [47]. In the current study ICH induced 
changes in CBF, CBV, edema, ADC, and BBB permeability were measured. Edema 
increased in the rim acutely, as CBF was reduced, but both normalized subacutely. Acute 
ADC values in the rim were not significantly affected so there was no evidence for ischemia, 
consistent with previous laboratory [48,49] and clinical investigations [50,51]. Some 
drawbacks in the present study are the relatively small sample size and lack of variations in 
ICH location along with the absence of a placebo control group. Nonetheless, the results 
serve as a proof of the principle and warrant larger trials. This is strengthened by other 
similarities in the present results to previous reports. For instance, 12 month mortality rate 
was 50% in a non-statin ICH group compared to 33.7% in a statin-exposed group [23]. In 
another study, statin use was the only variable also associated with lower 6-month mortality 
rate (12.5% in non-statin vs 0% in statin cohort); this study also reported a GOS of 4-5 in 
55% of statin-treated patients compared to 49.6% of controls [22], although no data on 
lesion size was reported. The present data also corroborate these data and also others from a 
previous report that showed no association between post-ICH statins and increased bleeding 
recurrence; for instance, Fitz Maurice, et al. have reported no increased rehemorrhage risk 
after post-ICH statin therapy [36].
Conclusion
Atorvastatin after ICH was safe and feasible in this study with no rebleeding observed 
following statin treatment. It should also be noted that none of the patients studied 
experienced any adverse effects during the study, and the planned MRI sequences were 
tolerable and obtainable. However, a potential weakness of this preliminary safety trial is 
non-inclusion of an untreated control group. Therefore, considering the prevailing paucity of 
effective treatments [52], future larger trials will require a comparison control group for MRI 
analysis to completely discern the statin treatment effects in acute ICH. There is also a need 
to address the known pleiotropic effects of the different statins available, their probable 
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varying degrees of efficacies alone and in combination with other putative neurovascular 
unit rescuers, in appropriate preclinical models [7].
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ICH Intracerebral Hemorrhage
GCS Glasgow Coma Score
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MRI Magnetic Resonance Imaging
T2WI T2-Weighted Imaging
DTI Diffusion Tensor Imaging
BBB Blood-Brain Barrier
SWI Susceptibility-Weighted Imaging
GOS Glasgow Outcome Score
CBF Cerebral Blood Flow
CBV Cerebral Blood Volume
ADC Apparent Diffusion Coefficient of Water
HMG-CoA 3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A
IRB Institutional Review Board
FDA Food and Drug Administration
L-L Look-Locker
3D 3-Dimensional
IRSPGR Inversion Recovery Spoiled Gradient Recalled Acquisition
TR Repetition Time
TE Echo Time
FA Flip Angle
BW Band Width
FOV Field of View
DCE-MRI Dynamic Contrast Enhanced MRI
FSE Fast Spin-Echo
EPI Echo Planar Imaging
SD Standard Deviation
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels
STITCH Surgical Trial in Traumatic Intra Cerebral Haemorrhage
Ipsil/Contral Ipsilateral/Contralateral
NINDS National Institute for Neurological Disorders and Stroke
NIH National Institutes of Health
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Figure 1. 
Plot of lesion volumes at acute (1), sub-acute (2) and chronic (3) time points. The lesion 
volume decreased steadily across time with both the core and rim regions decreasing. The 
decrease in lesion volume was significant between the acute and chronic time points.
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Figure 2. 
Representative images of a patient with ICH at acute, sub-acute and chronic time points. The 
upper row presents T2-weighted images showing the temporal evolution of the hematoma 
and peri-hematoma rim, from which the core and rim regions were identified. The 2nd and 
3rd rows show the corresponding SWI and T1 subtraction images, respectively. Finally, the 
bottom row presents the CBV maps from the 3 time points. There seemed to be some 
persistent CBV reductions, probably reflecting secondary effects of the ICH. It can be noted 
that no secondary post-ICH rebleeding was seen by SWI. The extent of the peri-hematoma 
rim acutely can be appreciated by visual comparison of the SWI and T2WI.
Knight et al. Page 13
Austin J Cerebrovasc Dis Stroke. Author manuscript; available in PMC 2017 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Average T2 values plotted as a function of time post-ICH. T2 values for the adjacent rim 
(left) and the central core (right) regions of interest located in the ipsilateral and 
corresponding contralateral hemispheres are shown at acute (1), sub-acute (2) and chronic 
(3) time points. The low T2 values in the core at acute and chronic time points probably is 
due to the presence of large amounts of deoxyhemoglobin and hemosiderin, respectively, 
whereas the elevated T2 subacutely probably reflects edema. In the rim region, the acute T2 
elevation was probably due to edema.
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Figure 4. 
Average CBF ratio (ipsilateral/contralateral) values shown plotted as a function of time post-
ICH. CBF ratios are shown for the adjacent rim (left) and the central core (right) regions of 
interest at acute (1), sub-acute (2) and chronic (3) time points. CBF levels in both the rim 
and core areas were low acutely. CBF in the rim, however, appeared to improve significantly 
over time, but not in the core.
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Figure 5. 
Average ADC values plotted as a function of time post-ICH. ADC values for the adjacent 
rim (left) and the central core (right) regions of interest located in the ipsilateral and 
corresponding contralateral hemispheres are shown at acute (1), sub-acute (2) and chronic 
(3) time points. The initial decline of ADC in the core area, while not reaching the same 
degree as seen with ischemic stroke, may be indicative of low CBF that eventually causes 
permanent injury. Conversely, there were no significant ADC changes noted in the rim area.
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